Advanced Recurrent Ovarian Cancer Market, Epidemiology, Pipeline, Drugs, Companies and Competitive Analysis by DelveInsight
Ovarian cancer is the most lethal gynaecological malignancy that presents at an advanced stage in 75% of patients. Ovarian cancer is predominantly a disease of older, postmenopausal women with the majority (>80%) of cases being diagnosed in women over 50 years. The exact cause of ovarian cancer remains unknown, but many associated risk factors have been identified. A woman’s reproductive history appears to contribute significantly to her lifetime risk of ovarian cancer. The three major types of ovarian cancer are epithelial, accounting for 90% of cases, germ cell (3%), and sexcord-stromal (2%). Epithelial cancers are further subdivided into serous (52%), endometrioid (10%), mucinous (6%), and clear cell (6%) tumours.
DelveInsight's "Advanced
Recurrent Ovarian Cancer Market Insights, Epidemiology, and Market
Forecast-2032" report delivers an in-depth understanding of the
Advanced Recurrent Ovarian Cancer, historical and forecasted epidemiology as
well as the Advanced Recurrent Ovarian Cancer market trends in the United
States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
View Report: https://www.delveinsight.com/report-store/advanced-recurrent-ovarian-cancer-market
Some facts of Advanced
Recurrent Ovarian Cancer Market Report:
·
According to a study by J.A. Ledermann et al.,
titled, “Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up”, the
estimated number of new ovarian cancer cases in Europe in 2012 was 65,538 with
42,704 deaths.
·
There is variation in the incidence rate across
the continent with a higher incidence in northern European countries. In the
USA, there were ∼20,400 newly diagnosed cases and 14,400 deaths in 2009.
·
Ovarian cancer is the fifth most common type of
cancer in women and the fourth most common cause of cancer death in women. The
estimated lifetime risk for a woman developing ovarian cancer is about one in 54.
·
According to the American Cancer Society,
approximately 20% of ovarian cancer cases, particularly high-grade serous
tumours, are estimated to be due to inherited mutations that confer elevated
risk, the majority from BRCA1 and BRCA2.
Some of Advanced
Recurrent Ovarian Cancer Pipeline Drugs are
·
Bevacizumab
·
MM-121
·
OTL38
·
2X-121
·
PX-Survivac
·
Oregovomab
·
HPN536
·
PRGN-3005 UltraCAR-T
·
And Many Others
To get detailed List
of Advanced Recurrent Ovarian Cancer
Drugs in pipeline, Request for Sample Report: https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-market
Key Benefits of Advanced Recurrent Ovarian Cancer Market
Report:
- The
report covers the descriptive overview of Advanced Recurrent Ovarian
Cancer, explaining its causes, signs and symptoms, pathophysiology,
diagnosis and currently available therapies
- Comprehensive
insight has been provided into the Advanced Recurrent Ovarian Cancer
epidemiology and treatment in the 7MM
- Additionally,
an all-inclusive account of both the current and emerging therapies for
Advanced Recurrent Ovarian Cancer is provided, along with the assessment
of new therapies, which will have an impact on the current treatment
landscape
- A
detailed review of the Advanced Recurrent Ovarian Cancer market;
historical and forecasted is included in the report, covering drug
outreach in the 7MM
- The
report provides an edge while developing business strategies, by
understanding trends shaping and driving the global Advanced Recurrent
Ovarian Cancer market
View Report: https://www.delveinsight.com/report-store/advanced-recurrent-ovarian-cancer-market
Some of Advanced Recurrent Ovarian Cancer Companies:
·
MedImmune LLC
·
Merrimack Pharmaceuticals
·
On Target Laboratories
·
Oncology Venture
·
ImmunoVaccine Technologies
·
OncoQuest
·
Harpoon Therapeutics
·
Precigen
·
And Many Others
To get detailed
information of Advanced Recurrent
Ovarian Cancer Companies in pipeline, Request for Sample Report: https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-market
Table of Contents
1. Key Insights
2. Executive Summary
of Advanced Recurrent Ovarian Cancer
3. Competitive
Intelligence Analysis for Advanced Recurrent Ovarian Cancer
4. Advanced
Recurrent Ovarian Cancer: Market Overview at a Glance
5. Advanced
Recurrent Ovarian Cancer: Disease Background and Overview
6. Patient Journey
7. Advanced
Recurrent Ovarian Cancer Epidemiology and Patient Population
8. Treatment Algorithm,
Current Treatment, and Medical Practices
9. Advanced
Recurrent Ovarian Cancer Unmet Needs
10. Key Endpoints of
Advanced Recurrent Ovarian Cancer Treatment
11. Advanced
Recurrent Ovarian Cancer Marketed Products
List to be continued
in report
12. Advanced
Recurrent Ovarian Cancer Emerging Therapies
List to be continued
in report
13. Advanced
Recurrent Ovarian Cancer: Seven Major Market Analysis
14. Attribute
analysis
15. 7MM: Market
Outlook
16. Access and
Reimbursement Overview of Advanced Recurrent Ovarian Cancer
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight
Capabilities
22. Disclaimer
View Report: https://www.delveinsight.com/report-store/advanced-recurrent-ovarian-cancer-market
Other Reports:
·
Surgical
Site Infection Ssi Market
·
Wound
Closure Devices Market
·
Bone
Anchored Hearing Systems Market
·
Hereditary
Spastic Paraplegias Market
·
Chronic
Obstructive Pulmonary Disease Copd Market
·
22q11.2
Deletion Syndrome Market
·
Implantable
Infusion Pumps Market
·
Pediatric
Growth Hormone Deficiency Pghd Market
·
Diagnostic
Imaging Equipment Market
·
Continuous
Renal Replacement Therapy Machines Market
·
Rituximab
Biosimilars Insight
·
Autosomal
Recessive Congenital Ichthyosis Market
·
Cardiac
Biomarkers Testing Devices Market
·
Chronic
Refractory Cough Market
·
Advanced
Renal Cell Carcinoma Market
·
Pulmonary
Hypertension Associated With Interstitial Lung Disease Market
·
Upper
Limb Hypertonia Market
·
Prosthetic
Joint Infection Market
·
Parkinson
S Disease Levodopa Induced Dyskinesia Market
·
Non-Cystic
Fibrosis Bronchiectasis Market
·
Higher-Risk
Chronic Myelomonocytic Leukemia Market
·
Graft
Versus Host Disease Market
·
Clostridium
Difficile Infections Cdi Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused
exclusively on life sciences. It supports pharma companies by providing
end-to-end comprehensive solutions to improve their performance.
Contact us
Ankit Nigam
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/
Connect With Us at:
LinkedIn | Facebook | Twitter
Comments
Post a Comment